Keros Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Keros Therapeutics, Inc. (KROS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.42 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-03
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 4.42M shares, a 9.35% decline year-over-year.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 3.70M shares, a 36.21% decline year-over-year.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 4.47M shares, a 15.49% decline year-over-year.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 4.88M shares, a 6.87% decline year-over-year.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 4.52M shares, a 16.80% decline from fiscal 2024.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.43M shares, a 23.61% increase from fiscal 2023.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.39M shares, a 24.39% increase from fiscal 2022.
- Keros Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.53M shares, a 25.70% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.42M shares 10-Q · filed 2026-08-03 | 4.08M shares 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | 3.70M shares 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 4.52M shares 10-K · filed 2026-03-04 | |||
| 2025-09-30 | 4.47M shares 10-Q · filed 2025-11-05 | 4.74M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 4.88M shares 10-Q · filed 2026-08-03 | 4.91M shares 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | 5.79M shares 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 5.43M shares 10-K · filed 2026-03-04 | |||
| 2024-09-30 | 5.29M shares 10-Q · filed 2025-11-05 | 5.29M shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 5.24M shares 10-Q · filed 2025-08-06 | 5.24M shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 5.22M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 4.39M shares 10-K · filed 2025-02-26 | |||
| 2023-09-30 | 4.42M shares 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | 3.53M shares 10-K · filed 2025-02-26 | |||
| 2021-12-31 | 2.81M shares 10-K · filed 2023-03-03 | |||
| 2021-03-31 | 2.80M shares 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 2.50M shares 10-K · filed 2022-03-09 | |||
| 2020-09-30 | 2.48M shares 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | 2.48M shares 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | 11.86M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 7.75M shares 10-K · filed 2021-03-25 | |||
| 2019-09-30 | 7.83M shares 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 9.17M shares 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | 7.52M shares 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |